In addition, immunohistochemistry (IHC) assay (Figure 7C) and flow cytometry (FCM) analysis (Figure 7D,E) revealed that RA and anti‐PD‐1 antibody combination led to higher proportions of tumor‐infiltrating CD8+ T cells in TILs and CD103+ CD11c+ cDC1 cells than either therapy did alone. The gene discussed is CD8A; the disease is neoplasm.